Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: An Eastern Cooperative Oncology group pilot study

Cancer

Volumn 85, Issue 2, 1999, Pages 358-367

  Tallman, Martin S ^a   Lee, Sandra ^b   Sikic, Branimir I ^c   Paietta, Elisabeth ^d   Wiernik, Peter H ^d   Bennett, John M ^e   Rowe, Jacob M ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Cyclosporine; Multidrug resistance; P glycoprotein expression

Indexed keywords

CYCLOSPORIN; CYTARABINE; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LIVER TOXICITY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMATITIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINE; CYTARABINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MDR; HUMANS; LEUKEMIA, MYELOID; LEUKOPENIA; LIVER; MALE; MIDDLE AGED; MITOXANTRONE; P-GLYCOPROTEIN; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032942270     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990115)85:2<358::AID-CNCR13>3.0.CO;2-0     Document Type: Article

References (73)

1. Yates J, Glidwell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 1982;60:454-62.
2. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-74.
3. Wiernik PH, Banks PLC, Case DC Jr., Arlin ZA, Periman PO, Todd MB, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79:313-9.
4. Tallman MS, Appelbaum FR, Amos D, Goldberg RS, Livingston RB, Mortimer J, et al. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with asparaginase and amsacrine with etoposide. J Clin Oncol 1985;5:918-26.
5. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-82.
6. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994;331: 896-903.
7. Champlin R, Gajewski J, Nimer S, Vollset S, Landow E, Winston D, et al. Post-remission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 1990;8:1199-206.
8. Stein RS, Flexner JM. Successful re-induction therapy for active myelogenous leukemia with cytosine arabinoside and daunorubicin. Cancer Treat Rep 1979;63:11-2.
9. Peterson BA, Bloomfield CD. Re-induction of complete remission in adults with acute nonlymphocytic leukemia. Leukemia Res 1981;5:81-8.
10. Velu T, Delbusscher L, Stryckmans P. Daunorubicin in patients with relapsed and refractory acute nonlymphocytic leukemia previously treated with anthracycline. Am J Hematol 1988;27:224-5.
11. Willemze R, Zwaan FE, Colpin G, Keuning JJ. High-dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Hematol 1983;29:141-6.
12. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983;62:361-9.
13. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside for remission re-induction of acute nonlymphocytic leukemia. J Clin Oncol 1985;3: 992-7.
14. Hines JD, Oken MM, Mazza JJ, Deller AM, Streeter RR, Glick JH. High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. J Clin Oncol 1984;2:545-9.
15. Zittoun R, Bury J, Stryckmans P, Löwenberg B, Peetermans M, Rozendaal KY, et al. Amsacrine and high-dose cytosine in acute leukemia. Cancer Treat Rep 1985;69:1447-8.
16. Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep 1984;68:87-99.
17. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1978;63:1727-33.
18. Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 1985;28:51-75.
19. Pasta I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987;316:1388-93.
20. Chaudhary PH, Robinson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85-94.
21. Slater LM, Sweet P, Stupecky M, Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphocytic leukemia in vitro. J Clin Invest 1986;7:1405-8.
22. Osieka R, Seeber S, Pannenbacker R, Soll D, Glatte P, Schmidt CG. Enhancement of etoposide-induced cytotoxicity cyclosporin A. Cancer Chemother Pharmacol 1986;18: 198-2002.
23. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Hagenbeek T, Valerio D. Over expression of the MDR-1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990;45:263-8.
24. Hermeijer H, Sonneveld P, Bass F, Nooter K. Expression of MDR-1 and MDR-3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. J Natl Cancer Inst 1990;82:1133-40.
25. Yahanda AM, Adler KM, Fisher G, Brophy NA, Hardy R, Halsey J, et al. A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992; 10:1624-34.
26. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trail of modulation of multidrug resistance. J Clin Oncol 1992;10: 1635-42.
27. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:1652-60.
28. Sikic BI. Modulation of multidrug resistance at the threshold [editorial]. J Clin Oncol 1993;11:1629-35.
29. Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance in drug resistance in clinical oncology and hematology. Hematol Oncol Clin North Am 1995;(9):363-82.
30. Paciucci PA, Ohnuma T, Cuttner J, Silver RT, Holland JF. Mitoxantrone in patients with acute leukemia in relapse. Cancer Res 1993;43:3919-22.
31. Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 1983;67:389-90.
32. Moore JO, Olsen GA. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 1984; 11(Suppl I):41-6.
33. Arlin Z, Dukart G. Phase I-II trial of mitoxantrone in acute leukemia. Invest New Drugs 1985;3:213-7.
34. Meyer P, Ho AD, Ehninger G, Mjaaland I, Heidemann E, Seither E. Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Invest New Drugs 1985;3:203-6.
35. Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA. A clinical and pharmaceutical study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 1987;5:391-7.
36. Bennett JM, Lymann GM, Cassileth PA, Glick JH, Oken MM. A Phase II trial of VP16 in adults with refractory acute myeloid leukemia. An ECOG study. Am J Clin Oncol 1984;7: 471-3.
37. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well-tolerated regimen. J Clin Oncol 1988;6:213-7.
38. Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF. Mitoxantrone and Ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1987; 1:565-7.
39. Helnemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol 1988;22:205-11.
40. Hiddemann W, Kreutzman H, Straif K, Ludwig R, Mertelsmann R, Donhuijsen-Ant R, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 1987;69:744-9.
41. Rowe JM, Andersen JW, Mazza JJ. Treatment of relapsed and refractory AML with mitoxantrone and etoposide: a study of the ECOG Acute Leukemia IV Prognostic Factors. In: Buchner T, et al., editors. Berlin: Springer-Verlag, 1994:235-8.
42. Amadori S, Arcese W, Isacchi G, Meleni G, Petti MC, Monarca B, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 1991;7:1210-4.
43. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travada P, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991;77:1894-900.
44. Archimbaud E, Thomas X, Leblond V. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone and cytarabine-86 trial. J Clin Oncol 1995;13: 11-8.
45. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Gallon DAG, Gralnick HR, et al. Proposals for the classification of the acute leukemias. French-American British (FAB) Cooperative Group. Br J Haematol 1976;33:451-8.
46. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994; 12:835-42.
47. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute - sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8: 813-9.
48. Paietta E, Andersen J, Racevskis J, Gallagher R, Bennett J, Yunis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8:968-73.
49. Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P, Wiernik PH. Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reversing agents in vitro. Blood Rev 1995;9:47-52.
50. Simon R. Optimal two-stage designs for phase II clinical studies. Control Clin Trials 1989;10:1-10.
51. Bishop YMM, Fridenberg SE, Holland PW. Discrete multivariate analysis, theory and practice. Cambridge, MA: MIT Press, 1975.
52. Kaplan EL, Meier R. Nonparametric estimation from incom-plete observation. J Am Stat Assoc 1958;53:457-81.
53. Cox DR, Oakes D. Analysis of survival data. Chapman and Hall Priesler, H.D. Failure of remission induction during the treatment of acute leukemia. Med Pediatr Oncol 1984;4: 275-6.
54. Priesler HD. Failure of remission induction during the treatment of acute leukemia. Med Pediatr Oncol 1987;4:275-6.
55. Advani R, Saba H, Rowe JM, Tallman M, Wiernik P, Ramek J, et al. Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) [abstract]. Blood 1996;88:215a.
56. Paietta E, Neuberg D, Rowe JM, Cassileth PA, Wiernik PH. The prognostic significance of immunoprofiles in adult acute myeloid leukemia (AML) varies with age: a comparative analysis of the Eastern Cooperative Oncology Group (ECOG) database [abstract]. Proc Am Soc Clin Oncol 1997; 16:13.
57. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, et al. Correlation of multidrug resistance (MDRI) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/Efflux+ and MDRI+ /Effluxcases. Blood 1995;86:2329-42.
58. Sonneveld P, Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukemia. Br J Haematol 1990;75:208-11.
59. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, et al. Cyclosporine A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996;4:223-9.
60. Wilson WH, Bates SE, Fojo A, Bryant C, Zhan Z, Regis J, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
61. Solary E, Witz B, Caillot D, Moreau Ph, Desablens B, Cahn JY, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996;88:1198-205.
62. Twentyman PR, Bleehen NM. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporine A. Eur J Cancer 1991;27:1639-42.
63. Jiang X-R, Kelsey SM, Yu Y-L, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukemic cells by non-immunosuppressive cyclosporine D analogue, SDZ PSC 833. Br J Haematol 1995;90:375-83.
64. Boesch D, Gaveriavy C, Jachez B, Pewtier-Manzanedo A, Bellinger P, Loor F. In vivo circumvention of P-glycoprotein-mediated drug resistance in tumor cells with SDZ PSC 833. Cancer Res. 1991;51:4226-30.
65. Ludescher C, Eisterer W, Hilbe W, Hofman J, Thaler J. Decreased potency of MDR-modulators under serum conditions determined by a functional assay. Br J Haematol 1995; 1:652-9.
66. Lehnert M, DeGiuli R, Kunke K, Emerson S, Dalton WS, Salmon SE. Serum can inhibit reversal of multidrug resistance by sensitizers. Eur J Cancer 1996;32:862-7.
67. Paietta E. Classical multidrug resistance in acute myeloid leukemia. Med Oncol 1997;14:53-60.
68. te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nootec K, Hagemeijer A, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 1993;82:3157-62.
69. Schneider E, Cowan KH, Bader H. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995;85:186-93.
70. Hart SM, Ganeshaguru K, Hoffbrand AI, Prentice HG, Mehta AB. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia. Leukemia 1994;8:163-8.
71. List AF, Spier CS, Abbaszadegan M, Grogan TM, Greer JP, Wolff SN, et al. Non-P-glycoprotein (PGP) mediated multidrug resistance (MDR): identification of a novel drug resistance phenotype with prognostic relevance acute myeloid leukemia (AMI.) [abstract]. Blood 1993;83:443a.
72. Tidefelt U, Elmhorn-Rosenburg A, Paul C, Hao XY, Manervik B, Eriksson EC. Expression of glutathione transferase p as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res 1992;52:3281-5.
73. Kornblau SM, Estey E, Madden T, Tran T, Zhao S, Consoli U, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by Sdz PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997;15: 1796-802.